- Home
- LFS vs ATYR Comparison
LFS vs ATYR Comparison
Compare LFS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFS | ATYR |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 49.2M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LFS | ATYR |
|---|---|---|
| Price | $2.18 | $0.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | ★ 1.4M | 590.9K |
| Earning Date | 04-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $0.40 |
| 52 Week High | $12.49 | $6.50 |
Technical Indicators
Market Signals| Indicator | LFS | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 44.21 |
| Support Level | $2.11 | $0.46 |
| Resistance Level | $2.33 | $0.59 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 28.36 | 18.46 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).